Secondary chemoprevention using short period (3 months) of LHRHa as an option for men with low-risk localized prostate cancer (LRPC) before active surveillance (AS).
Olivier Cussenot
No relevant relationships to disclose
Sarah Drouin
No relevant relationships to disclose
Christophe Egrot
No relevant relationships to disclose
Jean-Nicolas Cornu
No relevant relationships to disclose
Philippe Sebe
No relevant relationships to disclose
Pierre Mozer
No relevant relationships to disclose
Pierre Conort
No relevant relationships to disclose
Christophe Vaessen
No relevant relationships to disclose
Francois Haab
No relevant relationships to disclose
Marc-Olivier Bitker
No relevant relationships to disclose
Morgan Roupret
No relevant relationships to disclose